JERUSALEM, Israel--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), Israel’s leading drug development company, today announced that it has signed in-license agreements to develop and commercialize two new therapeutic candidates: BL-3040, a small molecule for the treatment of estrogen-regulated malignancies and osteoporosis; and BL-3050, a protein complex for the treatment of atherosclerosis. This marks the third and fourth in-licensing agreements signed by BioLineRx since its IPO in February 2007, bringing the total number of drugs under development by the Company to fourteen.
